Drug intelligence / Profile preview

XT1061

Development stage: Phase 1
Lead developer: Xi'an Xintong Pharmaceutical Research
Modality: Small Molecules
Administration: Oral

Overview

XT1061 is a novel small molecule antiviral drug under development for the treatment of chronic hepatitis B. It acts as an inhibitor of the hepatitis B virus (HBV) nucleocapsid (capsid) protein assembly, thereby interfering with viral replication. The drug is being developed by Xi'an Xintong Pharmaceutical Research and is currently in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and food effects in healthy volunteers. As a new molecular entity targeting HBV capsid assembly, it represents a potential advance in chronic hepatitis B therapy[1][2][3][5].

Targets

HBc (Hepatitis B virus core protein)

Beyond the preview

Go deeper on XT1061.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XT1061.

Explore the full profile